NEWS

NEWS

Total 83

63
NeoImmuneTech to Display its Environmental, Social, and Governance Activities on its Corporate Website
2022-06-30
62
A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity
2022-06-15
61
NeoImmuneTech to Present at Upcoming BIO International Convention
2022-06-13
60
NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors
2022-06-07
59
NeoImmuneTech to Present at Immuno-Oncology Summit Europe 2022
2022-05-19
58
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase II Study of NT-I7 and Pembrolizumab in Recurrent Glioblastoma
2022-05-11
57
NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting
2022-04-28
56
NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022
2022-04-14
55
NeoImmuneTech to Celebrate First Year of Trading at KOSDAQ
2022-03-16
54
NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting
2022-03-10

1 2 3 4 5 >>>